As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value amid broader market declines. In this environment, a good stock is often characterized by strong fundamentals and the potential for growth despite external pressures, making it an attractive consideration for those looking to navigate current market challenges.
Name | Current Price | Fair Value (Est) | Discount (Est) |
Provident Financial Services (NYSE:PFS) | $17.76 | $34.77 | 48.9% |
MINISO Group Holding (NYSE:MNSO) | $20.29 | $40.47 | 49.9% |
Brookline Bancorp (NasdaqGS:BRKL) | $11.18 | $22.02 | 49.2% |
Berkshire Hills Bancorp (NYSE:BHLB) | $26.97 | $53.19 | 49.3% |
Pure Storage (NYSE:PSTG) | $50.11 | $99.37 | 49.6% |
Archrock (NYSE:AROC) | $25.11 | $49.33 | 49.1% |
Five9 (NasdaqGM:FIVN) | $33.35 | $65.87 | 49.4% |
JBT Marel (NYSE:JBTM) | $131.88 | $259.85 | 49.2% |
Nutanix (NasdaqGS:NTNX) | $77.08 | $153.67 | 49.8% |
Mobileye Global (NasdaqGS:MBLY) | $14.39 | $28.77 | 50% |
Click here to see the full list of 196 stocks from our Undervalued US Stocks Based On Cash Flows screener.
Let's take a closer look at a couple of our picks from the screened companies.
Overview: Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for treating cystic fibrosis, with a market cap of approximately $124.11 billion.
Operations: The company generates its revenue primarily from its pharmaceuticals segment, which amounted to $11.02 billion.
Estimated Discount To Fair Value: 41.3%
Vertex Pharmaceuticals is currently trading at a significant discount to its estimated fair value of US$828.23, with shares priced at US$486.22, reflecting a valuation gap over 40%. This undervaluation is underpinned by strong cash flow potential, despite recent net losses and executive changes. The company anticipates robust revenue growth driven by new product launches like JOURNAVX and expanded indications for TRIKAFTA. Vertex's strategic buybacks and collaborations further enhance its financial positioning amidst ongoing investments in innovative therapies.
Overview: EQT Corporation is involved in the production, gathering, and transmission of natural gas with a market cap of $29.10 billion.
Operations: The company generates revenue of $5.04 billion from its Oil & Gas - Integrated segment.
Estimated Discount To Fair Value: 42.1%
EQT is trading at US$50, significantly below its estimated fair value of US$86.32, highlighting a valuation gap over 40%. Despite recent shareholder dilution and lower profit margins, EQT's earnings are projected to grow substantially at 33.1% annually, outpacing the US market. The company has initiated strategic debt restructuring and joint ventures to strengthen its financial position while maintaining robust revenue growth forecasts exceeding market averages.
Overview: Flutter Entertainment plc is a sports betting and gaming company with operations in the United Kingdom, Ireland, Australia, the United States, Italy, and other international markets, and it has a market cap of approximately $48.13 billion.
Operations: The company's revenue segments are comprised of $5.68 billion from the US, $3.44 billion from the UK and Ireland, $1.42 billion from Australia, and $3.03 billion from international markets.
Estimated Discount To Fair Value: 10.5%
Flutter Entertainment is trading at US$266.15, below its estimated fair value of US$297.26, reflecting a moderate valuation gap. The company reported significant revenue growth to US$14.05 billion in 2024 from the previous year's US$11.79 billion and turned a net income of US$43 million from a prior loss of over one billion dollars. With projected annual earnings growth of 62.53% and expected profitability within three years, Flutter shows strong cash flow potential despite trading slightly under fair value estimates.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:VRTX NYSE:EQT and NYSE:FLUT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.